| Seamus David Lonergan, MD | |
|
3360 Octavia St Apt 6, San Francisco, CA 94123-2224 | |
| (415) 775-9619 | |
| (415) 775-9619 |
| Full Name | Seamus David Lonergan |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 3360 Octavia St Apt 6, San Francisco, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1407953391 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | A90573 (California) | Primary |
| Entity Name | Century Integrated Partners, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447615711 PECOS PAC ID: 6406151703 Enrollment ID: O20160224002152 |
News Archive
Covidien plc today reported results for the second quarter of fiscal 2013 (January - March 2013). Second-quarter net sales of $3.10 billion increased 5% from the $2.95 billion reported in the second quarter a year ago. Foreign exchange rate movement lowered the quarterly sales growth rate by two percentage points.
Daiichi Sankyo Company, Limited, announced today that it has initiated a new large-scale pivotal Phase III trial for edoxaban, its investigational oral Factor Xa inhibitor. This new study, called HOKUSAI (pronounced hoe·koo·sigh) VTE, is evaluating the safety and efficacy of edoxaban in reducing recurrent venous thromboembolic (VTE) complications in patients with deep vein thrombosis (DVT) and/or pulmonary embolism (PE).
A specific form of vitamin E improved the most severe form of fatty liver disease in some children, according to a study funded by the National Institutes of Health. Results appear in the April 27 issue of the Journal of the American Medical Association. A previous study found vitamin E effective in some adults with the disease.
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that researchers at McGill Center for Studies in Aging, Douglas Research Institute and Montreal Neurological Institute presented results of a post-mortem brain tissue study using Navidea's investigational Fluorine-18 labeled β-amyloid imaging agent, NAV4694, during the Alzheimer's Association International Conference in Boston, MA.
› Verified 6 days ago
| Entity Name | Ies Mobile Medicine Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992320758 PECOS PAC ID: 2466878624 Enrollment ID: O20200818003032 |
News Archive
Covidien plc today reported results for the second quarter of fiscal 2013 (January - March 2013). Second-quarter net sales of $3.10 billion increased 5% from the $2.95 billion reported in the second quarter a year ago. Foreign exchange rate movement lowered the quarterly sales growth rate by two percentage points.
Daiichi Sankyo Company, Limited, announced today that it has initiated a new large-scale pivotal Phase III trial for edoxaban, its investigational oral Factor Xa inhibitor. This new study, called HOKUSAI (pronounced hoe·koo·sigh) VTE, is evaluating the safety and efficacy of edoxaban in reducing recurrent venous thromboembolic (VTE) complications in patients with deep vein thrombosis (DVT) and/or pulmonary embolism (PE).
A specific form of vitamin E improved the most severe form of fatty liver disease in some children, according to a study funded by the National Institutes of Health. Results appear in the April 27 issue of the Journal of the American Medical Association. A previous study found vitamin E effective in some adults with the disease.
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that researchers at McGill Center for Studies in Aging, Douglas Research Institute and Montreal Neurological Institute presented results of a post-mortem brain tissue study using Navidea's investigational Fluorine-18 labeled β-amyloid imaging agent, NAV4694, during the Alzheimer's Association International Conference in Boston, MA.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Seamus David Lonergan, MD 3360 Octavia St, Apt 6, San Francisco, CA 94123-2224 Ph: (415) 775-9619 | Seamus David Lonergan, MD 3360 Octavia St Apt 6, San Francisco, CA 94123-2224 Ph: (415) 775-9619 |
News Archive
Covidien plc today reported results for the second quarter of fiscal 2013 (January - March 2013). Second-quarter net sales of $3.10 billion increased 5% from the $2.95 billion reported in the second quarter a year ago. Foreign exchange rate movement lowered the quarterly sales growth rate by two percentage points.
Daiichi Sankyo Company, Limited, announced today that it has initiated a new large-scale pivotal Phase III trial for edoxaban, its investigational oral Factor Xa inhibitor. This new study, called HOKUSAI (pronounced hoe·koo·sigh) VTE, is evaluating the safety and efficacy of edoxaban in reducing recurrent venous thromboembolic (VTE) complications in patients with deep vein thrombosis (DVT) and/or pulmonary embolism (PE).
A specific form of vitamin E improved the most severe form of fatty liver disease in some children, according to a study funded by the National Institutes of Health. Results appear in the April 27 issue of the Journal of the American Medical Association. A previous study found vitamin E effective in some adults with the disease.
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that researchers at McGill Center for Studies in Aging, Douglas Research Institute and Montreal Neurological Institute presented results of a post-mortem brain tissue study using Navidea's investigational Fluorine-18 labeled β-amyloid imaging agent, NAV4694, during the Alzheimer's Association International Conference in Boston, MA.
› Verified 6 days ago
Paul Robinson, Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1230 Arguello Blvd Apt 2, San Francisco, CA 94122 Phone: 415-948-8836 | |
Frederick D Pitts Jr., MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 229 7th St, San Francisco, CA 94103 Phone: 415-503-6042 Fax: 415-503-6099 | |
Georgina Lisseth Calderon, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1501 10th Ave, Apt. 1, San Francisco, CA 94122 Phone: 323-514-0964 | |
Timothy Bauer Duncan, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 2333 Buchanan St, San Francisco, CA 94115 Phone: 209-342-2300 Fax: 209-524-4240 | |
Bichhuong M Dinh, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3555 Cesar Chavez, San Francisco, CA 94110 Phone: 240-447-1281 | |
Dr. Lauren Elizabeth Chalwell, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1001 Potrero Avenue Department Of Emergency Medicine, San Francisco General Hospital,, San Francisco, CA 94110 Phone: 415-206-5753 | |
Dr. Jeremy Lacocque, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1001 Potrero Ave, San Francisco, CA 94110 Phone: 628-206-8000 |